Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer "This Break Through Cancer project brings a ...

Researchers have been able to identify at least three distinct subtypes of a rare type of bone cancer for the first time, which could transform clinical trials and patient care. While genetic ...

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its ...

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

(RTTNews) - OS Therapies, Inc. (OSTX), a clinical-stage biopharma company specializing in immunotherapies and antibody-drug conjugates, has launched a new subsidiary, OS Animal Health, Inc., to lead ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that ...

Researchers from UC Davis and Lawrence Livermore National Laboratory developed and studied a new material — engineered bone marrow, or eBM. Engineered bone marrow offers a better way to study ...